First Tracks Biotherapeutics, Inc. (TRAX) is currently trading at $16.03 with a Wall Street consensus price target of $38.12, implying potential upside of 137.8% over the next 12 months. 8 analysts currently cover TRAX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $54.0, while the most cautious has a target of $30.0.
TRAX operates in the Healthcare sector with a market capitalisation of $559M. The stock is down 15.6% year-to-date and is currently trading near the lower end of its 52-week range of $14.72 – $26.8.
Other Healthcare stocks with comparable size and valuation.
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →